Material Event Form 8 K

Item 8.01 Other Events.

On December 13, 2024, Bone Biologics Corporation (the "Company") filed a prospectus supplement to update the maximum amount of shares the Company is eligible to sell under the At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, dated September 27, 2024 to $832,009. The Company previously sold approximately $846,288 of shares of Common Stock pursuant to the Sales Agreement pursuant to a prior prospectus supplement dated September 27, 2024. A copy of the legal opinion as to the legality of the $832,009 of shares of Common Stock issuable under the Sales Agreement and covered by the prospectus supplement is filed as Exhibit 5.1 attached hereto.